Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 27 Aug 2015
At a glance
- Drugs 2X 121 (Primary) ; Carboplatin (Primary) ; Eribulin (Primary)
- Indications Breast cancer; Ovarian cancer
- Focus Adverse reactions
- 24 Aug 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 30 Mar 2015 Planned initiation date changed from 1 Mar 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov.
- 27 Mar 2015 New trial record